Showing 1,061 - 1,080 results of 63,864 for search '(( 01 ((1 decrease) OR (a decrease)) ) OR ( 50 ((mean decrease) OR (nn decrease)) ))', query time: 1.40s Refine Results
  1. 1061
  2. 1062

    Decreased s.c. growth of CNDT 2.5 cells after systemic administration of DOPC liposome-conjugated siNRP-2. by Shaija Samuel (341436)

    Published 2013
    “…NRP-2-siRNA DOPC-treatment led to a significant decrease in tumor growth compared with cntr siRNA DOPC-treatment (264.4 mm<sup>3</sup> vs. 751.3 mm<sup>3</sup>, respectively; *<i>p</i> = 0.01). …”
  3. 1063
  4. 1064
  5. 1065

    Annual number of outpatient visits in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

    Published 2025
    “…<p>In the recurrence group, mean outpatient visits (± standard deviation) decreased from 13.6 ± 3.0 to 11.9 ± 5.0, 8.1 ± 3.9, and 7.8 ± 3.2 at 1, 2, and 3 years postoperatively, respectively (Kruskal-Wallis test, P < 0.001; Dunn’s test, **P < 0.01). …”
  6. 1066

    rAd-p53 induces apoptosis in HCC cell lines with increased Fbxw7 and decreased c-Myc and Cyclin E. by Kangsheng Tu (428934)

    Published 2013
    “…<p>A) MTT activity was measured after infecting Hep3B cells with rAd-p53 in an MOI gradient to determine their IC<sub>50</sub> after 48 h. Mean OD values were used to calculate the IC<sub>50</sub> via the modified Kou-type method: lgIC<sub>50</sub> = Xm-I (P-(3-Pm-Pn)/4), in which Xm: lg maximum dose; I: lg (maximum dose/ adjacent dose); P: sum of positive response rate; Pm: the largest positive response rate; Pn: the smallest positive response rate. …”
  7. 1067
  8. 1068
  9. 1069
  10. 1070

    Annual number of outpatient visits in all eyes. by Yasuyuki Sotani (20114144)

    Published 2025
    “…<p>Mean visit frequency (mean ± standard deviation) significantly decreased from 11.5 ± 4.3 preoperatively to 8.8 ± 4.1, 5.0 ± 3.4, and 4.4 ± 3.2 visits in the first, second, and third postoperative years, respectively (Kruskal–Wallis test, P < 0.001; Dunn’s test, **P < 0.01). …”
  11. 1071
  12. 1072
  13. 1073

    Chamber. by Yoichiro Kitajima (4319455)

    Published 2022
    Subjects:
  14. 1074
  15. 1075

    Protocols. by Yoichiro Kitajima (4319455)

    Published 2022
    Subjects:
  16. 1076
  17. 1077
  18. 1078
  19. 1079

    Urothelial PAR4-induced HMGB1 intensity decrease is mediated through MIF. by Dimitrios E. Kouzoukas (746678)

    Published 2016
    “…Quantitative image analysis (D) revealed that average urothelial HMGB1 immunofluorescence significantly decreased after intravesical PAR4-AP administration in comparison to control peptide-treated animals (** <i>p</i> ≤ 0.01), indicating urothelial release of HMGB1. …”
  20. 1080